Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Intractable & Rare Diseases Research|November 29, 2023
Release and impact of China's "Second List of Rare Diseases"Mi Tang, Yan Yang, Ziping Ye, et al.
Plos One|June 16, 2017
Risk factors and protective factors associated with incident or increase of frailty among community-dwelling older adults: A systematic review of longitudinal studiesZeyun Feng, Marjolein Lugtenberg, Carmen Franse, et al.
Patient Preference and Adherence|July 31, 2023
Comparison of Rare and Common Diseases in the Setting of Healthcare Priorities: Evidence of Social Preferences Based on a Systematic ReviewYichun Gu, Anqi Wang, Huan Tang, et al.
Bioscience Trends|November 27, 2018
China issues the National Essential Medicines List (2018 edition): Background, differences from previous editions, and potential issuesJiangjiang He, Mi Tang, Ziping Ye, et al.
Annals of Translational Medicine|September 17, 2021
COVID-19 as an opportunity to reveal the impact of large hospital expansion on the healthcare delivery system: evidence from Shanghai, ChinaYuqian Chen, Linan Wang, Xin Cui, et al.
Drug Discoveries & Therapeutics|June 16, 2020
Prospects for development of group purchasing organizations (GPOs) in China within the context of national centralized drug procurementMinxing Chen, Lixuan Cong, Jiangjiang He, et al.
Intractable & Rare Diseases Research|September 17, 2019
Marketing of drugs for rare diseases is speeding up in China: Looking at the example of drugs for mucopolysaccharidosisQi Kang, Jiahao Hu, Nuo Yang, et al.
Patient Preference and Adherence|August 22, 2022
Preference to Family Doctor Contracted Service of Patients with Chronic Disease in Urban China: A Discrete Choice ExperimentHaode Wang, Hui Sun, Chunlin Jin, et al.
BMC Geriatrics|November 11, 2025
Association between living arrangements and health outcomes among stroke survivors in ChinaBifan Zhu, Duo Chen, Xiaohui Hou, et al.
BMJ Open|December 3, 2024
Analysing the effects of National Centralised Drug Procurement and Price Negotiation Policies on novel hypoglycaemic drug usage and costs in Shanghai, China: an interrupted time series analysisJie Song, Wei Guo, Chunlin Jin, et al.
Pageof 7